<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05112731</url>
  </required_header>
  <id_info>
    <org_study_id>2021AGLIANICO</org_study_id>
    <nct_id>NCT05112731</nct_id>
  </id_info>
  <brief_title>Role of Glycation and Inflammation in Acute Ischemic Heart Disease</brief_title>
  <acronym>AGLIANICO</acronym>
  <official_title>Action of Glycation and Inflammation in Operative Ischemic Heart Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GEK Srl</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Istituto Clinico Città Studi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>GEK Srl</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study requires the consecutive enrollment of 60 patients following the first event of&#xD;
      acute myocardial infarction, evaluating B-Cell Activating Factor (BAFF) and methylglyoxal&#xD;
      (MGO) levels in the acute setting (pre-reperfusion) and 3 months after reperfusion.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study requires the consecutive enrollment of 60 patients at admission for first acute&#xD;
      myocardial infarction. At enrollment, before reperfusion, a blood sample is obtained to&#xD;
      measure B-Cell Activating Factor (BAFF) and methylglyoxal (MGO) levels in the acute setting.&#xD;
      This measure is then repeated at follow-up visit 3 months after reperfusion. The aim of the&#xD;
      study is to identify specific subsets of patients and evaluate biomarkers variations.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of Inflammatory Biomarkers (BAFF) linked to ischemic event and outcome</measure>
    <time_frame>Day 0</time_frame>
    <description>elevation of BAFF levels</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Identification of Glycation Biomarkers (MGO) linked to ischemic event and outcome</measure>
    <time_frame>Day 0</time_frame>
    <description>elevation of MGO levels</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Identification of biomarkers variations (BAFF) complications and outcome</measure>
    <time_frame>After 3 months</time_frame>
    <description>variation of BAFF from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identification of biomarkers variations (MGO) complications and outcome</measure>
    <time_frame>After 3 months</time_frame>
    <description>variation of MGO from baseline</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Myocardial Infarction</condition>
  <condition>Glycation End Products, Advanced</condition>
  <condition>Inflammation</condition>
  <condition>Heart Injuries</condition>
  <condition>Heart Inflammation</condition>
  <arm_group>
    <arm_group_label>First Ischemic Cardiac Event</arm_group_label>
    <description>Measurement of BAFF and MGO at hospitalization (before reperfusion) and after 3 months during follow-up</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>BAFF and MGO</intervention_name>
    <description>measurement of BAFF and MGO levels before reperfusion and after 3 months</description>
    <arm_group_label>First Ischemic Cardiac Event</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        60 consecutive patients admitted in the ED for first myocardial infarction who meet&#xD;
        eligibility criteria&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  hospitalization for first myocardial infarction (STEMI or NSTEMI)&#xD;
&#xD;
          -  age between 18 and 80&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  uncompensated T2DM (HbA1c &gt;53mmol/mol)&#xD;
&#xD;
          -  use of anti-CD20 treatment&#xD;
&#xD;
          -  chronic anti-inflammatory treatment for autoimmune disease (i.e. DMARDs, high dose&#xD;
             FANS, cortisonic drugs)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michele Bianchi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Clinico Città Studi</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Altin Palloshi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Clinico Città Studi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mattia Cappelletti, MD</last_name>
    <phone>0286882476</phone>
    <email>mattia.cappelletti@studiospeciani.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Istituto Clinico Città Studi</name>
      <address>
        <city>Milano</city>
        <zip>20131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Michele Bianchi, MD</last_name>
    </contact>
    <investigator>
      <last_name>Altin Palloshi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Evans JDW, Dobbin SJH, Pettit SJ, Di Angelantonio E, Willeit P. High-Sensitivity Cardiac Troponin and New-Onset Heart Failure: A Systematic Review and Meta-Analysis of 67,063 Patients With 4,165 Incident Heart Failure Events. JACC Heart Fail. 2018 Mar;6(3):187-197. doi: 10.1016/j.jchf.2017.11.003. Epub 2018 Jan 10.</citation>
    <PMID>29331272</PMID>
  </reference>
  <reference>
    <citation>Mariathas M, Allan R, Ramamoorthy S, Olechowski B, Hinton J, Azor M, Nicholas Z, Calver A, Corbett S, Mahmoudi M, Rawlins J, Simpson I, Wilkinson J, Kwok CS, Cook P, Mamas MA, Curzen N. True 99th centile of high sensitivity cardiac troponin for hospital patients: prospective, observational cohort study. BMJ. 2019 Mar 13;364:l729. doi: 10.1136/bmj.l729.</citation>
    <PMID>30867154</PMID>
  </reference>
  <reference>
    <citation>Francis Stuart SD, De Jesus NM, Lindsey ML, Ripplinger CM. The crossroads of inflammation, fibrosis, and arrhythmia following myocardial infarction. J Mol Cell Cardiol. 2016 Feb;91:114-22. doi: 10.1016/j.yjmcc.2015.12.024. Epub 2015 Dec 29. Review.</citation>
    <PMID>26739214</PMID>
  </reference>
  <reference>
    <citation>Zouggari Y, Ait-Oufella H, Bonnin P, Simon T, Sage AP, Guérin C, Vilar J, Caligiuri G, Tsiantoulas D, Laurans L, Dumeau E, Kotti S, Bruneval P, Charo IF, Binder CJ, Danchin N, Tedgui A, Tedder TF, Silvestre JS, Mallat Z. B lymphocytes trigger monocyte mobilization and impair heart function after acute myocardial infarction. Nat Med. 2013 Oct;19(10):1273-80. doi: 10.1038/nm.3284. Epub 2013 Sep 15.</citation>
    <PMID>24037091</PMID>
  </reference>
  <reference>
    <citation>Akhand AA, Hossain K, Mitsui H, Kato M, Miyata T, Inagi R, Du J, Takeda K, Kawamoto Y, Suzuki H, Kurokawa K, Nakashima I. Glyoxal and methylglyoxal trigger distinct signals for map family kinases and caspase activation in human endothelial cells. Free Radic Biol Med. 2001 Jul 1;31(1):20-30.</citation>
    <PMID>11425486</PMID>
  </reference>
  <reference>
    <citation>Khan MA, Schultz S, Othman A, Fleming T, Lebrón-Galán R, Rades D, Clemente D, Nawroth PP, Schwaninger M. Hyperglycemia in Stroke Impairs Polarization of Monocytes/Macrophages to a Protective Noninflammatory Cell Type. J Neurosci. 2016 Sep 7;36(36):9313-25. doi: 10.1523/JNEUROSCI.0473-16.2016.</citation>
    <PMID>27605608</PMID>
  </reference>
  <reference>
    <citation>Blackburn NJR, Vulesevic B, McNeill B, Cimenci CE, Ahmadi A, Gonzalez-Gomez M, Ostojic A, Zhong Z, Brownlee M, Beisswenger PJ, Milne RW, Suuronen EJ. Methylglyoxal-derived advanced glycation end products contribute to negative cardiac remodeling and dysfunction post-myocardial infarction. Basic Res Cardiol. 2017 Sep 1;112(5):57. doi: 10.1007/s00395-017-0646-x.</citation>
    <PMID>28864889</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 20, 2021</study_first_submitted>
  <study_first_submitted_qc>October 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2021</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AGEs</keyword>
  <keyword>BAFF</keyword>
  <keyword>Myocardial Infarction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Heart Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

